MA33702B1 - Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps - Google Patents

Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps

Info

Publication number
MA33702B1
MA33702B1 MA34818A MA34818A MA33702B1 MA 33702 B1 MA33702 B1 MA 33702B1 MA 34818 A MA34818 A MA 34818A MA 34818 A MA34818 A MA 34818A MA 33702 B1 MA33702 B1 MA 33702B1
Authority
MA
Morocco
Prior art keywords
represent
conjugates
mitonzinoid
antibodies
preparation
Prior art date
Application number
MA34818A
Other languages
Arabic (ar)
English (en)
Inventor
Alain Commercon
Claudia Fromond
Vincent Mikol
Fabienne Parker
Ingrid Sassoon
Hervé Bouchard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33702(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33702B1 publication Critical patent/MA33702B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE FORMULE (I) : DANS LAQUELLE : ALK REPRÉSENTE UN GROUPE ALKYLÈNE EN C1-C6 ; X1 ET X2 REPRÉSENTENT CHACUN INDÉPENDAMMENT L'UN DES GROUPES SUIVANTS : -CH=CH-, -CO-, -CONR-, -NRCO-, -COO-, -OCO-, -OCONR-, -NRCOO-, -NRCONR'-, -NR-, -S(O)N (N = 0, 1 OU 2) OU -O- ; R ET R' REPRÉSENTENT CHACUN INDÉPENDAMMENT H OU UN GROUPE ALKYLE EN C1-C6 ; I REPRÉSENTE UN ENTIER DE 1 À 40, DE PRÉFÉRENCE DE 1 À 20 ET DE PRÉFÉRENCE ENCORE DE 1 À 10 ; J REPRÉSENTE UN ENTIER CORRESPONDANT À 1 LORSQUE X2 REPRÉSENTE -CH=CH- ET 2 LORSQUE X2 NE REPRÉSENTE PAS -CH=CH- ; ZB REPRÉSENTE UNE SIMPLE LIAISON, -O- OU -NH- ET RB REPRÉSENTENT H OU UN GROUPE ALKYLE EN C1-C6, CYCLOALKYLE EN C3-C7, ARYLE, HÉTÉROARYLE OU HÉTÉROCYCLOALKYLE EN C3-C7 ; OU ZB REPRÉSENTE UNE SIMPLE LIAISON ET RB REPRÉSENTE HAL. L'INVENTION PORTE ÉGALEMENT SUR L'UTILISATION DESDITS MAYTANSINOÏDES POUR PRÉPARER DES CONJUGUÉS AVEC UN ANTICORPS AYANT UNE AFFINITÉ POUR DES CELLULES TUMORALES.
MA34818A 2009-10-02 2012-04-27 Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps MA33702B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305939 2009-10-02
PCT/IB2010/054417 WO2011039721A1 (fr) 2009-10-02 2010-09-30 Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps

Publications (1)

Publication Number Publication Date
MA33702B1 true MA33702B1 (fr) 2012-10-01

Family

ID=41698152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34818A MA33702B1 (fr) 2009-10-02 2012-04-27 Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps

Country Status (25)

Country Link
US (1) US20120276124A1 (fr)
EP (1) EP2483279A1 (fr)
JP (1) JP2013506653A (fr)
KR (1) KR20120091166A (fr)
CN (1) CN102741260A (fr)
AR (1) AR078471A1 (fr)
AU (1) AU2010302247A1 (fr)
BR (1) BR112012007305A2 (fr)
CA (1) CA2774916A1 (fr)
CL (1) CL2012000820A1 (fr)
CR (1) CR20120147A (fr)
EA (1) EA201270473A1 (fr)
EC (1) ECSP12011756A (fr)
IL (1) IL218740A0 (fr)
MA (1) MA33702B1 (fr)
MX (1) MX2012003998A (fr)
NI (1) NI201200051A (fr)
NZ (1) NZ599045A (fr)
PE (1) PE20121534A1 (fr)
PH (1) PH12012500649A1 (fr)
TN (1) TN2012000115A1 (fr)
TW (1) TW201117814A (fr)
UY (1) UY32913A (fr)
WO (1) WO2011039721A1 (fr)
ZA (1) ZA201202328B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
UY32914A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
ME03353B (fr) 2011-03-29 2019-10-20 Immunogen Inc Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
MY171008A (en) 2011-03-29 2019-09-23 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
NO2789793T3 (fr) 2012-10-24 2018-01-27
US20150290342A1 (en) * 2012-10-24 2015-10-15 Polytherics Limited Drug-protein conjugates
CN104688740A (zh) * 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
US20160143914A1 (en) * 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
CN103483357B (zh) * 2013-10-12 2015-11-18 齐鲁制药有限公司 一种抗体-美登素偶联物的中间体新晶型及其制备方法
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
US9562059B2 (en) * 2013-12-02 2017-02-07 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
CN106243127B (zh) 2015-06-09 2021-01-26 凯惠科技发展(上海)有限公司 抗体药物偶联物、中间体、制备方法、药物组合物及应用
JP6638970B2 (ja) * 2015-06-30 2020-02-05 株式会社 東北テクノアーチ ヘテロ型単分散ポリエチレングリコール、ヘテロ型単分散ポリエチレングリコール製造用中間体の製造方法
EP3373937B1 (fr) 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Conjugués anticorps anti-her22-maytansine et méthodes d'utilisation de ceux-ci
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
CN107652219B (zh) 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (fr) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugués d'un anticorps contre CD44 et d'un maytansinoide
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
AU2004238289A1 (en) * 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
MXPA05011811A (es) 2003-05-20 2006-02-17 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
EP1669358A1 (fr) 2004-12-07 2006-06-14 Aventis Pharma S.A. Agents cytotoxiques comprenant des nouveau taxanes
EP2399893B1 (fr) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions contenant des acides aminés et des polypeptides non naturels, procédés les impliquant et leurs utilisations
ATE535529T1 (de) 2005-08-09 2011-12-15 Millennium Pharm Inc Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
CA3000520C (fr) * 2005-08-24 2023-04-04 Immunogen, Inc. Procede de preparation de conjugues maytansinoides-anticorps
EP1832577A1 (fr) 2006-03-07 2007-09-12 Sanofi-Aventis Promédicament amélioré d'analogues de CC-1065
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
SG189817A1 (en) * 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
UY32914A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2

Also Published As

Publication number Publication date
NZ599045A (en) 2013-09-27
TW201117814A (en) 2011-06-01
EP2483279A1 (fr) 2012-08-08
UY32913A (es) 2011-04-29
PH12012500649A1 (en) 2012-11-12
KR20120091166A (ko) 2012-08-17
CA2774916A1 (fr) 2011-04-07
CR20120147A (es) 2012-06-01
TN2012000115A1 (en) 2013-09-19
WO2011039721A1 (fr) 2011-04-07
PE20121534A1 (es) 2012-12-03
AU2010302247A1 (en) 2012-04-26
IL218740A0 (en) 2012-06-28
JP2013506653A (ja) 2013-02-28
CL2012000820A1 (es) 2012-08-31
EA201270473A1 (ru) 2013-02-28
AR078471A1 (es) 2011-11-09
NI201200051A (es) 2012-08-09
ECSP12011756A (es) 2012-07-31
US20120276124A1 (en) 2012-11-01
BR112012007305A2 (pt) 2016-12-06
ZA201202328B (en) 2014-06-25
CN102741260A (zh) 2012-10-17
MX2012003998A (es) 2012-04-20

Similar Documents

Publication Publication Date Title
MA33702B1 (fr) Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps
MX2008010481A (es) Compuestos que tienen afinado para el receptor f-ht6.
ZA200702700B (en) Diagnostic compounds
WO2009023844A3 (fr) Composés substitués en position 3' ayant une affinité vis-à-vis du récepteur 5-ht<sb>6</sb>
MX2010003394A (es) Derivado de gamma-aminoacido biciclico.
MX2009002492A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2009151598A8 (fr) Diazacarbazoles et procédés d’utilisation
MA33761B1 (fr) Dispersion solide de rifaximine
MA31988B1 (fr) Derives d'aminopyrazole
WO2009054497A1 (fr) Nouveau composé présentant une affinité pour l'amyloïde
WO2008083056A3 (fr) Ligands pour imagerie d'innervation cardiaque
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
WO2008081631A1 (fr) Composé polymérisable et composition polymérisable
WO2008147812A3 (fr) Composés 4' substitués ayant une affinité de récepteur 5-ht6
WO2005110416A3 (fr) 2-arylpyrimidines disubstituees en 4,5
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
IL189883A0 (en) Isoquinolines as igf-1r inhibitors
WO2009016954A1 (fr) Fluide de travail du métal à base aqueuse
MA31526B1 (fr) Nouveaux herbicides
SE0400708D0 (sv) New compounds and use thereof
WO2008107771A3 (fr) 2',3'-di-o-acyl-5-fluoronucléosides
BRPI0414732A (pt) piridilacetilenos para uso como radiotraçadores e agentes de imageamento
DE602006013828D1 (en) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren